Results 91 to 100 of about 1,800 (153)

Protective effects of N-acetylcysteine against irinotecan – induced pulmonary toxicity in female albino rats

Zanco Journal of Medical Sciences
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a deadly lung illness characterized by progressive lung fibrosis and deteriorating lung function, with the uncertain origin and few therapeutic options. Chemotherapy such as Irinotecan (IRI)
Hawrin Burhan Khudhur, Ansam Al-Hassani
doaj   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Suna Lin, Linjie Li, JiJun Chen, Zhaokun Tao, Lifeng Zhang, Junqing Mao, Jinhu Wang   +6 more
wiley   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China.

PLoS ONE
BackgroundThe cost-effectiveness of liposome irinotecan (II) (HR070803) in combination with 5-fluorouracil and leucovorin as a treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma offering a potential new standard ...
Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng   +5 more
doaj   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source